T 2165/08 (Bi-cyclic nucleoside analogues/EXIQON) of 11.02.2014
- European Case Law Identifier
- ECLI:EP:BA:2014:T216508.20140211
- Date of decision
- 11 February 2014
- Case number
- T 2165/08
- Petition for review of
- -
- Application number
- 98942516.0
- IPC class
- C07H 21/00
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen (C)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- T 2165/08 Bi-cyclic nucleoside analogues/EXIQON 2013-03-06
- Abstracts for this decision
- -
- Application title
- Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
- Applicant name
- Exiqon A/S
- Opponent name
- Isis Pharmaceuticals, Inc.
- Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention R 88(1)European Patent Convention R 88(4)Rules of procedure of the Boards of Appeal Art 16(2)
- Keywords
- Assessment of apportioned costs
- Catchword
- -
- Cited cases
- -
ORDER
For these reasons it is decided that:
The costs to be paid by the appellant to the respondent pursuant to the board's decision of 6 March 2013 are assessed at £1,200.